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Pancreatic neuroendocrine tumors (pNETs) comprise with gastro-
intestinal carcinoids, the main groups of gastrointestinal neuro-
endocrine tumors (GI-NETs). Although these two groups of GI-NETs
share many features including histological aspects; over-/ectopic
expressionof somatostatin receptors; the ability toectopically secrete
hormones/peptides/amines which can result in distinct functional
syndromes; similar approaches used for tumor localization and some
aspects of treatment, it is now generally agreed they should be con-
sidered separate. They differ in their pathogenesis, hormonal syn-
dromes produced, many aspects of biological behaviour and most
important, in their response to certain anti-tumour treatment (che-
motherapy, molecular targeted therapies). In this chapter the clinical
features of the different types of pNETs will be considered as well as
aspects of their diagnosis and medical treatment of the hormone-
excess state. Emphasis will be on controversial areas or recent ad-
vances. The other aspects of the management of these tumors (sur-
gery, treatment of advanced disease, tumor localization) are not dealt
with here, because they are covered in other chapters in this volume.
 2013 Elsevier Ltd. All rights reserved.ch, Building 10, Room 9C-103, National Institutes of Health, Bethesda, MD
2 0600.
.gov (R.T. Jensen).
td. All rights reserved.
T. Ito et al. / Best Practice & Research Clinical Gastroenterology 26 (2012) 737–753738IntroductionPancreatic neuroendocrine tumors (pNETs) are neuroendocrine tumors (NETs) that are found pri-
marily in the pancreas and upper small intestine and are frequently also referred to as pancreatic
endocrine tumors (PETs) [1,2]. Although diverse in clinical presentation and aspects of treatment, all of
the subtypes of pNETs share many common features including their pathology, most features of their
biologic behaviour, characteristics of their advanced disease states andmany aspects of their treatment,
especially in patients with advanced metastatic disease [3–6]. Because of this they are generally con-
sidered together. Although they sharemany featureswith gastrointestinal carcinoids (GI-NETs) including
aspects of their pathology [both express neuroendocrine markers (chromogranin A (CgA), neuron spe-
ciﬁc enolase, synaptophysin), overexpress somatostatin receptors], their biological behaviour in that
both can be associatedwith functional syndromes or can be nonfunctional, localizationmethods used for
both and aspects of the treatment of patients with advanced disease, and both are classiﬁed now as
gastrointestinal neuroendocrine tumors(NETs), pNETs andGI-NETs (carcinoids) are generally considered
separately [2,6–8]. This occurs not only because of their different functional syndromes (carcinoids
syndrome vs. pNETs syndromes), but also recent studies show they have a different molecular patho-
genesis, differences in certain aspects of their biological behaviours, and they respond differently to
different antitumour treatments (chemotherapy, everolimus) in patients with advanced disease [2,7–9].
In this chapter only selected aspects of pNETs will be covered, concentrating on recent advances.
Speciﬁcally, the chapter will focus on the clinical presentation of pNETs today, their diagnosis and
differential diagnosis, the importance of recognition of the pNET as part of an accompanying inherited
syndrome, and the medical management of the hormone excess-state. This restrictive approach is
taken because in this Volume separate chapters deal with many aspects of the management of pNETs.
Speciﬁcally, separate chapters deal with the pathology of pNETs, as well as tumor markers, pNETs
localization, surgery and treatment of advanced disease in patients withmalignant pNETs using various
modalities [biologic agents (interferon, somatostatin), chemotherapy, chemoembolization or other
liver directed therapy, PRRT and newer targeted therapies (everolimus, sunitinib, other tyrosine kinase
inhibitors)]. Furthermore, many of these aspects have been covered in recent reviews including re-
views covering all aspects of the management of pNETs [1,2,4,5], covering the different therapies for
patients with advanced metastatic disease with pNETs [3,8,10,11], surgical treatment [4], and the pa-
thology/classiﬁcation of pNETs [6,9,12].General features of pNETs
There are ten different commonly recognized pNETs which are listed in Table 1. Nine of these is
associated with a speciﬁc functional syndrome including gastrinomas (Zollinger–Ellison syn-
drome), insulinomas, glucagonomas, VIPomas (Verner–Morrison syndrome, pancreatic cholera,
WDHA syndrome), GRFomas (growth hormone releasing factor secreting), ACTHomas, somatos-
tatinomas, pNETs causing carcinoid syndrome and pNETs causing hypercalcaemia (PTHrPomas)
[2,4]. One pNETs syndrome is not associated with a speciﬁc hormonal syndrome and is frequently
referred to as a nonfunctional pNETs (NF-pNET)(also as a PPoma) [11]. None of the latter terms are
really correct as NF-pNETs, like other pNETs, in 60–100% secrete various peptides such as CgA,
neuron speciﬁc enolase, pancreatic polypeptide (50–70%),ghrelin, neurotensin, motilin, or subunits
of human chorionic gonadotrophin (alpha or beta subunits) which do not cause any speciﬁc clinical
syndrome [2,4,5,13–15]. In addition to these generally accepted pNET subtypes, there are a number
of other very rare pNETs with functional syndromes in which only a few cases have been reported
(Table 2). These include pNETs ectopically secreting erythropoietin resulting in erythroblastosis
[16]; pNETs secreting renin resulting in hypertension [17]; pNETs secreting GLP-1 or IGF-2 which is
associated with hypoglycemia [18,19]; and pNET secreting luteining hormone causing masculin-
ization [20,21]. An enteroglucagon secreting PET has been described mimicking a glucagonoma but
also with giant duodenal villi present which resembles features reported with renal/duodenal NETs
secreting enteroglucagon as well as a metastatic NET of unknown primary secreting GLP-1, GLP-2
and PYY (Table 2) [22–25]. Other hormone-excess states due to over-secretion of gastrointestinal
Table 1
Established pancreatic neuroendocrine tumor subtypes and syndromes (pNETS)(most frequent).
pNET Syndrome name Primary location(s) Incidence
(# new/100,000/yr)
Malignancy
(%)
Hormone
causing
syndrome
Functional pNETs
Gastrinoma Zollinger-Ellison
syndrome
Pancreas (30%)
Duodenum (60–70%)
Other (5–10%)
0.5–1.5 60–90% Gastrin
Insulinoma Insulinoma Pancreas (100%) 1–3 5–15% Insulin
VIPoma Verner-Morrison
Pancreatic cholera
WDHA
Pancreas 85–95%
Other (neural,
periganglionic,
adrenal)(10%)
0.05–0.2 70–90% Vasoactive
intestinal
peptide
Glucagonoma Glucagonoma Pancreas (100%) 0.01–0.1 60–75% Glucagon
Somatostastinoma Somatostastinoma Pancreas (50–60%
Duodenal/jejunal
(40–50%)
<0.1%. uncommon 40–60% Somatostatin
GRFoma GRFoma Pancreas (30%)
Lung (54%)
Jejunal (75%)
Other [adrenal, foregut,
retroperitoneal)(13%)
Unknown 30–50% Growth
hormone
releasing factor
ACTHoma ACTHoma 4–25% of all ectopic
Cushing’s syndrome
<0.1%, uncommon 95% ACTH
PET causing
carcinoid
syndrome
PET causing
carcinoid syndrome
Pancreas (100%)(<1% of
all carcinoid syndrome)
Uncommon
(<50 cases)
60–90% Serotonin
Tachykinins
PET causing
hypercalcaemia
PTHrPoma Pancreas (100%) <0.1%.
Uncommon
>85% PTHrP, other
unknown
Nonfunctional
(NF) pNET
PPomas NF-PET Pancreas (100%) 1–3 60–90% None. Secrete
pancreatic
polypeptide
(PP) (60–85%),
chromogranin A
but cause
no symptoms,
Abbreviations: PP, pancreatic polypeptide; ACTH, adrenocorticotropic hormone; GRF, growth hormone releasing factor, PPoma-
pNET secreting pancreatic polypeptide; PTHrP, parathyroid hormone related peptide. WDHA, watery diarrhoea, hypokalemia,
and achlorhydria.
Table 2
Very rare and other possible functional pNET syndromes (1–5 cases reported).
pNET secreting: Symptoms/signs Ref
I. Very rare pNETs (1–5 cases)
Luteinizing hormone Altered libido, menstrual abnormalities, hirsutism, infertility [20,21]
Renin Hypertension [17]
GLP-1 Hypoglycemic symptoms [18]
IGF-2 Hypoglycemic symptoms [19]
Erythropoietin Polycythemia [16]
Enteroglucagon Small intestinal hypertrophy
Colonic/jejunal stasis, malabsorption with or without
glucagonoma symptoms/signs
[23], renal/duodenal
tumor¼ [24,25]
II. Proposed pNET syndromes
Calcitonin Diarrhoea [2,26,27]
Neurotensin Motility, vascular abnormalities [23,28]
Pancreatic polypeptide Watery diarrhoea with or without hypokalemia [28–31,109]
Ghrelin Effects on appetite, body weight [32]
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secreting PYY resulting in constipation [20,21]; secreting renin or aldosterone causing alteration in
blood pressure; secreting serotonin causing the carcinoid syndrome and secreting GLP-1 and so-
matostatin resulting in diabetes and reactive hypoglycemia. These latter functional tumors are
usually not characterized as pNETs although the resemble aspects of pNETs as many are NETs.
PNETs frequently ectopically secrete PP(60–85%), neurotensin (30–67%), calcitonin (42%) and in
a lesser percentage, ghrelin (5–65%) [13,15,24]. Various studies have proposed that ectopic secre-
tion of these various hormones is also associated with functional clinical syndromes [2,23,26–32]
(Table 2). However, most studies support the conclusion that ectopic secretion of any of these four
hormones is not associated with a speciﬁc clinical syndrome and that they are clinically silent
[2,13,33,34].
Whereas pNETs have an incidence of 1–5/million/year clinically they are much more frequent in
autopsy studies occurring in 0.5–1.5%, demonstrating that <1/1000 cause a clinical syndrome [1,2].
pNETs comprise 1–2% of pancreatic neoplasms, however, in contrast to exocrine pancreatic neoplasms,
their incidence is increasing [35]. The relative frequency of the different pNETs appears to be changing
in recent reports. In older studies insulinomas and NF-pNETs were approximately equally frequent
making up 1/3 of all pNETs each, with gastrinomas slightly less frequent [2]. These were 8-fold more
frequent than VIPomas, 17-times more than glucagonomas, >20-fold more common that the others
with about 200 cases of somostatinomas worldwide reported. Recently NF-pNETs are being increasing
reported, often discovered when they are asymptomatic and without advanced disease and these are
making up twice the above percentages of pNETs in some recent studies [2,36,37]. This is a marked
change from the past where NF-pNETs were almost always found only late in their disease course
where they were already large in size (mean diameter-6 cm) with hepatic metastases present in 60–
85% [2,11,37].
All functional pNETs have two treatment problems: treatment is required of the hormone-excess
state and treatment needs to be directed at the pNET itself, because similar to NF-pNETs, in all cases
except for insulinomas (<10% malignant) the pNET show malignant behaviour in >50%(Table 1). In
older studies where effective treatments did not exist, many patients with functional pNETs died of the
uncontrolled hormone-excess state, demonstrating the importance of control of this state both acutely
and long-term. Increasingly, at present pNET patients are dying of the malignant behaviour of these
tumors, demonstrating the importance of surgical removal of a pNET, whenever possible and effective
control of the tumor in patients with advanced malignant disease [3,38]. Unfortunately, in many cases
the diagnosis is delayed and the patients already present with advanced metastatic disease making
surgical cure impossible.
The key management steps for all pNETs include: suspect the diagnosis, establish the diagnosis,
determined whether an inherited disorder is also present, control the hormone-excess state acutely
and long term, establish the primary tumor location and extent of disease using localization studies,
surgical resection of the tumor if possible, treatment directed against the pNET if malignant and if
unresectable, and ﬁnally the long-term follow-up of the patient [2]. Tumor localization, which is
considered in a detailed chapter, is essential in almost all management steps. pNET localization is
usually performed using cross-sectional imaging studies (CT scanning, ultrasound, MRI scan-
ning),somatostatin receptor scintigraphy (SRS) using either 111Indium- or 68Gallium-labelled so-
matostatin analogues with single photon emission tomography (in the case of 68 Gallium-analogues
by positron emission tomography),using endoscopic ultrasound, and in a few special cases by
measuring either basal hormonal gradients using portal venous sampling or measuring hepatic
venous gradients after selective intra-arterial injections of stimulants (calcium for insulinomas/
glucagonomas and secretin for gastrinomas) [1,2,4,39–45]. Because imaging modalities are dealt
with in separate chapters they will only be dealt with in this chapter in regard to overall man-
agement [1,2]. As mentioned above a number of these steps will be considered in detail below. Each
will be considered within the context of the speciﬁc pNET syndrome. However, before dealing with
the speciﬁc pNET syndromes it is important to ﬁrst brieﬂy discuss inherited pNET syndromes
because they frequently differ in aspects of clinical presentation, diagnosis, differential diagnosis,
prognosis, and many aspect of management from the majority of pNET patients who do not have an
inherited form (sporadic pNET) [46].
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Four different inherited syndromes are associated with the development pNETs; patients with
Multiple Endocrine Neoplasia type 1 (MEN1); von Hippel Lindau Disease (VHL); von Recklinghausen
disease (VRH)(neuroﬁbromatosis 1)(NF-1) and patients with tuberous sclerosis (Table 3).
Of these four inherited pNET syndromes the most important is MEN1, because 20–80%(mean 40–
65%) of all patients with this autosomal dominant disorder, develop a pNET that is clinically important
[46]. MEN1 occurs in 20–25% of all patients who develop gastrinomas and ZES, 4% of patients with
insulinomas, and<3%with the other pNETs [46]. MEN1 is classically characterized by the development
of tumors/hyperplasia in multiple endocrine tissues (parathyroid > pancreas > pituitary > adrenal)
[46] and is due to mutations in MEN1 gene at chromosome 11q13,which encodes for a 610 amino acid
protein, menin (Table 3). Menin interacts with numerous proteins/transcription factors, which are
important in regulating cell growth, cell cycle progression and a number of other cellular processes
(Table 3) [46]. Recently, in addition to these classical endocrine tumors, an increased occurrence of
tumors in other locations are reported in MEN1 patients, including carcinoids (gastric, thymic, lung)
[46,47]; CNS tumors (meningiomas, ependymomas) [46,48]; smooth muscle tumors (leiomyomas and
leiomyosarcomas) [46,49],and skin tumors (angioﬁbromas, collagenomas, lipomas, melanomas)
[46,50]. In terms of pNETs almost all patients with MEN1 have NF-PETs, however in most patients they
are microscopic and hence cause clinical symptoms in only 0–13% in different series (Table 3) [46]. In
contrast, functional pNETs (F-pNETs) requiring treatment are not infrequent, with ZES developing in
54% of MEN1 patients, with approximately 20% developing insulinomas, and the other F-pNETsTable 3
Inherited pNET syndromes.
Syndrome
Name
Prevalence
(per/100,000
population)
Genetic defect [function
altered protein]
Frequency
of pNETs
Type pNET
Multiple
endocrine
neoplasia
type 1
(MEN1)
1–10 11q13; encodes 610 amino
acid protein, Menin.
Nuclear protein which interacts
with pathways involved in
cell growth, cell cycle regulation,
genomic stability, apoptosis
80–100%
(microscopic)
20–80% clinical
NF-pNETs (80–100%,
micro), 0–15%-large
Gastrinoma (54%)
Insulinomas (18%)
Glucagonomas (3%)
Vipomas (3%)
GRFomas, SSomas <1%)
Von Hippel
Lindau
Disease (VHL)
2–3 3p25: encodes 232 amino acid
protein (pVHL)
Interacts with transcriptional
regulators that degrade
HIF; regulates cell cycle, VEGF
10–17% NF-pNETs(98%)
Neuroﬁbromatosis
1(NF-1)
(Von Recklinghausen
disease)
20–25,000 17q11.2 encodes 2484 amino
acid protein (neuroﬁbromin)
Has Ras GTPase activity, binds
microtubules, regulates mTor
growth, cell cytoskeleton
changes.
0–10% Duodenal Ssomas
Rare pNETs
Tuberosis sclerosis
(Bourneville disease)
10 9q34(TSC1): encodes 1164
amino
acid protein (hamartin);
1613 (TSC2)
encodes 1807 amino acid
protein (tuberin)
Interacts with PI3K
signaling cascade:
regulates mTor, GTPAse
activity affecting
cell growth, energy
regulation, response
to hypoxia, nutrients
Uncommon Rarely develop
functional pNETs,
NF-PETs
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from those arising sporadically. pNETs in patients with MEN1 develop at an earlier age than in patients
with sporadic disease, with the difference being 1 decade earlier for the development of ZES in MEN1
patients than those with sporadic gastrinomas [52]. Also many pNET subtypes (gastrinomas, NF-
PETs,insulinomas) are frequently multiple in MEN1,which is uncommon in sporadic cases [46,53].
All of the pNETs in MEN1 patients are intrapancreatic except for a rare somatostatinoma and gas-
trinomas which occur in >80% in the duodenum [46,54]. These duodenal gastrinomas are almost
invariably multiple in MEN1, are proposed to arise from G cell hyperplasia [55] and similar to sporadic
cases they are often small (<0.5 cm) and difﬁcult to localize preoperatively or ﬁnd at surgery [56–58].
Von Hippel Lindau disease (VHL) is an autosomal dominant disorder characterized by hemangio-
blastomas of the retina and cranio-spinal region, endolymphatic sac tumors, renal cell carcinomas or
cysts, pheochromocytomas, epididymal cystadenomas and pancreatic tumors or cysts in 35–77% of
patients [46,59]. VHL is caused by mutations in the VHL gene on chromosome 3p25 which encodes for
a 232 amino acid peptide, pVHL which is important in regulating angiogenic growth and the activity of
various mitotic factors (VEGF, PDGF, TGFa, erythropoietin) [46](Table 2). pNETs develop in 10–17% of
VHL patients, in almost all cases they are NF-PETs and are usually asymptomatic [46,60,61]. In contrast
to patients with MEN1 most VHL patients have a single pNET [46]. In 8–50% of patients with VHL, the
pNETs are malignant and metastases to the liver occur in 9–37% [46,60,61].
Von Recklinghausen disease (also called neuroﬁbromatosis-1)(NF-1) is a relatively common
inherited disorder characterized by the development of café-au-lait macules, neuroﬁbromas (cuta-
neous as well as deep-seated),skin-fold freckling, iris Lisch Nodules and bony dysplasia (Table 3)
[46,62]. CNS abnormalities are frequent with learning disorders (30–60%), attention deﬁcit hyperac-
tivity disorder and epilepsy [46,62]. NF-1 is due to mutations in the NF-1 gene on chromosome
17q11.2,which encodes for a 2485 amino acid protein, neuroﬁbromin, which is expressed widely in the
CNS, and affects cell growth, signaling regulated by activation of p21 Ras, and through themTor cascade
(Table 3) [46,62]. pNETs occur in only the minority of NF-1 patients (17%) and are almost exclusively
duodenal somatostatinomas (SSomas) [46,63,64]. Rare NF-1 patients have been reported with NF-
pNETs, ZES and insulinomas [46]. The duodenal SSomas characteristically occur in the periampullary
region, have a mean size of 2.8 cm (range 1–5), comprise 23% of all ampullary carcinoids (NETs) in
various series, have metastases in 30% of cases and are rarely associated with the clinical SSoma
syndrome (1–2%) [46].
Tuberous sclerosis is an autosomal dominant disorder characterized by the development of
hamartomas in almost any organ, disabling neurological features (autism, mental retardation, epi-
lepsy),dermatological features (hypomelanotic macules, shagreen patches, ungula ﬁbromas, facial
angioﬁbromas) and tumor-like hamartomatous lesions [46,65]. Tuberous sclerosis is caused by mu-
tation in one of two genes: either the TSC1 gene (encoding for hamartin) or the TSC2 gene (encoding for
tuberin) (Table 3). Hamartin and tuberin form a dimer and are important in a number of signaling
cascades involved in regulating mTor activity, protein translation, protein synthesis, growth, prolifer-
ation, cellular energy level regulation and nutrient availability [46]. A small percentage of tuberous
sclerosis patients have been reported with pNETs including F-PNETs (gastrinomas, insulinomas) and
NF-pNETs, of which some are malignant [46].
Recently a possible new genetic disorder, Mahvash disease, has been described (one patient) which
is due to a homozygous P86S mutation of the human glucagon receptor and is associated with the
development of a-cell hyperplasia, hyperglucagonemia and the development of NF-pNETs [25,66,67].
This disorder is reproduced in glucagon receptor deﬁcient mice [66,67]. At present it is unknown if this
disease is inherited and expressed in different generations.
Speciﬁc-pNET syndromes
Insulinoma
Insulinoma: clinical-presentation
The clinical presentation of insulinoma today has largely not changed from that described in older
studies [68–70]. Patients primarily present with features of neuroglycopenia (90%) [confusion,
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70%) [sweating, tremors, palpitations. weakness, hyperphagia] [2,68–70]. Typically these symptoms
are more likely to occur during times of fasting, delay in meals or during exercise. This later point is
particularly helpful in suggesting the potential correct diagnosis. This is pertinent at present, because
a recent increasing cause of patients with hypoglycemic symptoms is previous treatment for obesity
with gastric bypass [4]. Because of the very large numbers of these surgical procedures performed at
present this in time may be one of the most frequent causes of hypoglycemia. The hypoglycemic
symptoms after obesity surgery are frequently after a meal (postprandial hypoglycemia) rather that the
fasting hypoglycemia seen with insulinoma [4,71]. In some cases the bypass-induced hypoglycemia is
caused by the development of nesidioblastosis [72].
Insulinoma: diagnosis/differential-diagnosis
Any of the above symptoms, particularly associated with fasting or exercise should lead to
a suspicion of hypoglycemia. The presence of Whipple’s triad should lead to a suspicion of insuli-
noma, which consists of: 1. Symptoms of hypoglycemia, 2. Hypoglycemia(plasma glucose
2.2 mmol/l(40 mg/dl),3. Relief of symptoms with administration of glucose) [4,73]. Fasting hypo-
glycemia can be due to a number of causes besides insulinoma including nesidioblastosis, exogenous
use of insulin or hypoglycemia agents, the presence of insulin antibodies, insulin receptor antibodies,
noninsulinoma tumor associated hypoglycemia or various metabolic causes [69,73]. Different orga-
nizations recommend different criteria for the diagnosis of insulinoma [4,70,73]. The presence of
a serum glucose of <2.5 mmol/l(45 mg/dl) with a plasma insulin level >6 uU/ml (43 pmol/L) by
radioimmunoassay ( 3 uU/ml by immunochemoluminescent assay) combined with an increased
plasma C-peptide level (200 pmol/L),and a negative assay for the presence of sulfonylurea, es-
tablishes the diagnosis at the Mayo Clinic[70]. The gold standard to establish a diagnosis of insuli-
noma is the use of a 72 fast [70,73]. Most patients with insulinoma demonstrate a positive response
by 48 h, with 33% having symptoms within 12 h, 80% at 24 h, 90% at 48 h and >98% at 72 h [70].
Recent endocrine society clinical practice guidelines [73] conclude that endogenous hyper-
insulinemia exists if during the fast the patient develops symptoms/signs of hypoglycemia or both
with plasma concentrations of glucose <55 mg/dl (3.0 mmol l/L), plasma insulin at least 3.0 uU/ml
(18 pM),C-peptide of at least 0.6 ng/ml (0.2 nmol/L), proinsulin of at least 5 pM and as well as
a negative screen for oral hypoglycemic agents. One important point to be aware of is that plasma
insulin levels are being increasingly measured using insulin speciﬁc assays (immunochemilumi-
nescent or insulin-speciﬁc immunoradiometric assays) that do no cross react with proinsulin as did
the older radioimmunoassays and therefore give lower values of insulin. This has resulted in up to
60% of insulinoma patients having <6 uU/mL during the fast in some studies [2]. In one recent study
using these speciﬁc assays for insulin and proinsulin it was found that the best criteria for the
diagnosis of insulinoma was a combination of an increased proinsulin level and a fasting glucose
level <2.5 mmol/l (45 mg/dl).
Insulinoma: medical-treatment
The treatment of choice for insulinomas is surgical resection which is successful in >95% of cases
because insulinomas are rarely malignant (<10%), usually not multiple except in patients with MEN1
[46] and most can be localized preoperatively with conventional imaging studies, endoscopic ultra-
sound or in a very select few, insulin gradient sampling from hepatic veins after selective intra-arterial
injection of calcium [2,10,70]. Each of these aspects are dealt with in separate chapters in this volume
so they will not be dealt with further here.
Preoperatively and for the small group of patients with unresectable insulinomas, medical treat-
ment is needed. In addition to small frequent feedings, diazoxide, a benzothiadiazide that directly
inhibits insulin release, is generally the initial drug used [2,4,70,74]. Diazoxide controls the hypogly-
cemia in 50–60% of patients and has been effective for >20 yrs in some insulinoma patients [2,74,75].
Diazoxide treatment causes ﬂuid retention in approximately one-half the patients which is usually
managed with diuretics and is not troublesome [75],however it can also cause hirsutism and nausea
[2,74,75]. Various long-acting somatostatin analogues (octreotide, lanreotide) can also be used to
control the hypoglycemia in patients with insulinomas and are effective in 35–50% of patients,
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worse, by inhibiting counter-regulatorymechanisms [2,76]. Recently the mTOR inhibitor, everolimus is
reported to be effective in controlling the hypoglycemia in patients withmalignant insulinomas or who
cannot undergo surgical resection [3,4,77,78]. Other newer methods which are reported to be effect at
controlling the hypoglycemia in insulinoma patients where complete surgical resection can’t be per-
formed either because of advanced disease or the patient’s condition, include ethanol ablation of the
insulinoma [3,79] or the use of peptide radioreceptor therapy using radiolabeled somatostatin ana-
logues [3]. In patients with advanced disease with malignant insulinomas, treatments directed against
the tumor itself may help control the hypoglycemia, but they are not discussed further here as they are
dealt with in separate chapters in this volume.
Zollinger–Ellison syndrome (ZES)(gastrinoma)
ZES: clinical-presentation
Almost all patients with ZES initially present with symptoms due to the hypersecretion of gastric
acid which is due to the ectopic release of gastrin from the gastrinoma [2,52,80,81]. Only late in the
course of the disease due a small percentage present with symptoms and signs due to the advanced
tumor burden per se(pain, jaundice, bleeding, etc) [2,51,52,81]. The principal symptoms remain those
due to peptic ulcer disease or severe GERD (abdominal pain, nausea, heartburn, vomiting) with or
without diarrhoea [2,51,52,81,82]. In contrast to the past, at present patients only present with
a complication of peptic ulcer disease (bleeding, obstruction, penetration, perforation) in a minority of
patients (approximately 33%) [51,52,81]. Patients with ZES as part of the MEN1 syndrome (MEN1/ZES)
present at an earlier age (approximately 1 decade earlier) and may have relatively mild symptoms
which can be overlooked [51]. This is particularly the case if they have had parathyroid surgery for
hyperparathyroidism, which characteristically precedes the development of ZES in most, but not all
patients with MEN1/ZES [51,83]. The ectopic secretion of gastrin by the gastrinoma is inﬂuenced by the
degree of hypercalcaemia, so that post parathyroidectomy the acid hypersecretion can marked
decrease, result in amelioration of symptoms and can making it harder to suspect the presence of the
ZES in a MEN1/ZES patient [51,58,84].
ZES: diagnosis/differential-diagnosis
The diagnosis of ZES should be suspected in any patient with peptic ulcer disease/GERD which is
accompanied by diarrhoea, personal or family history of endocrinopathies, various laboratory ﬁndings
(hypercalcaemia, hypergastrinemia); the peptic disease/GERD is unusually severe, refractory to man-
agement or recurrent; or the peptic ulcer is in unusual locations or associated with peptic ulcer disease
complications (obstruction, bleeding, perforation, penetration [69,81]. Many patients with upper
abdominal pain undergo upper gastrointestinal endoscopy (GI) and the ﬁndings of prominent gastric
folds should suggest the possibility of ZES, as a recent study reports that due to the trophic effect of the
chronic hypergastrinemia on the gastric mucosa, prominent gastric folds are present in 92% of ZES
patients and should suggest this diagnosis to the endoscopist [52,82].
The initial study done today when ZES is suspected a determination of the fasting serum gastrin
(FSG) concentration. This is a very sensitive initial study to detect ZES as it is elevated in >98% of
patients with ZES [81,82,85,86]. However it is important to remember that hypergastrinemia has
a low speciﬁcity for the diagnosis of ZES because hypergastrinemia can result from a number of
other non-ZES conditions, some of which have a much higher incidence than ZES [81,82,85,86].
Particularly important is the fact that hypergastrinemia can occur in any condition that results in
hypo/achlorhydria (atrophic gastritis, pernicious anaemia, Helicobacter pylori infections, use of
potent antisecretory drugs)(physiological hypergastrinemia),as well as also be associated with other
conditions that cause hyperchlorhydria and hypergastrinemia, other than ZES (antral G cell hy-
perplasia, H. pylori infection, retained antrum syndrome, gastric outlet obstruction and occasionally
renal failure) [69,81,82,86]. Therefore, a normal FSG determination largely excludes ZES except
under special circumstances discussed below, however an elevated FSG is compatible with a diag-
nosis of ZES, however, alone does not make the diagnosis of ZES, no matter how high the elevation
of the FSG [86,87]. To establish the diagnosis of ZES it is necessary to demonstrate that the
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established that acid is present in the presence of the hypergastrinemia (off antisecretory drugs, see
below) [80]. The current recommended criteria for the diagnosis of ZES depends on the elevation of
the FSG [80,85,86,88]. If the FSG is >10 fold normal (usually>1000 pg/ml)(Nl<100 pg/ml) and the
gastric pH < 2,retained gastric antrum syndrome can be excluded by history, and the diagnosis is
established. Unfortunately, in 60% of ZES patients the FSG is <10-fold elevated and this overlaps
with the other conditions than can cause hyperchlorhydria and hypergastrinemia listed above
[81,85,86,88]. In these patients besides demonstrating hypergastrinenemia in the presence of
gastric pH < 2,a secretin test and a complete gastric analysis is recommended [80,85–88]. Patients
with ZES without previous gastric acid-reducing surgery characteristically have an elevated
basal acid output (90%) [80] and demonstrate an exaggerated response to intravenous secretin,
with an increase of 120 pg/ml recently shown to have a sensitivity of 94% and speciﬁcity of 100%
for ZES [88].
Unfortunately recent studies support the conclusion that the diagnosis of ZES is becoming more
complicated and more difﬁcult [86,87,89]. Two factors are responsible for this increased complexity.
First, a recent study demonstrates that many of the commercial gastrin kits that are used by many
laboratories to measure FSG levels are not reliable [90]. In this study [90] 7 of the 12 tested com-
mercial gastrin kits inaccurately assessed the true serum concentration of gastrin; primarily because
these kits used antibodies with inappropriate speciﬁcity that were not adequately validated. Both
overestimation and underestimation of the true FSG level occurred with different gastrin kits [90]. To
circumvent this problem either a laboratory that uses one of the 5 reliable gastrin kits listed in this
paper [90] needs to be used or an alternative is to refer the patient to a center with expertise in
making the diagnosis of ZES in your area, or if that is not possible, then consult with that center to
ﬁnd out what gastrin assay is reliable in your area [86]. A second factor that is complicating the
diagnosis of ZES is the widespread us of potent acid suppressant drugs such as PPIs (omeprazole,
lansoprazole, rabeprazole, esomeprazole, pantoprazole) [86,87,89,91]. PPIs are highly effective in ZES
and patients with idiopathic GERD or peptic ulcer disease in large part due to their long durations of
action (up to one week), which allow once or twice daily dosing in most cases [5,81,82,86]. PPIs delay
and complicate the diagnosis of ZES because their use in patients without ZES increases FSG in 80–
100% of cases, and not infrequently the increase is in ranges commonly seen in ZES patients
[2,82,86,89]. The result is that when a patient is taking PPIs, hypergastrinemia could be due to the PPI
or the underlying disease such as ZES. The classical method to resolve this is to stop the PPI
[2,82,86,87,89]. However, as pointed out in a recent paper [91],this can lead to severe peptic ulcer/
GERD complications in a patient who does have ZES, which led the authors to recommend that it not
be done. However, as subsequently pointed out in two commentaries [86,87],in the majority of
suspected ZES the diagnosis really cannot be made without stopping PPIs. Because of the potential
dangers of stopping PPIs it is recommend that the best approach is to refer the patient to a local
center with expertise in making the diagnosis of ZES. Alternatively, after establishing the patient has
no active peptic disease, one can substitute high dose ranitidine (600 mg every 4–6 h) for 5–7 days
then withdraw the ranitidine, and with liberal use of antacids, test the acid secretion in 12–24 h
[86,87]. The use of PPIs also complicates and delays the diagnosis of ZES, because it controls
symptoms in almost all ZES patients with the convenient doses used in treating patients with idi-
opathic peptic/GERD disease and thus masks the presentation, whereas H2 receptor antagonists
(cimetidine, ranitidine, nizatidine, famotidine) have a shorter duration of action/potency with the
result that higher doses are required and the ZES patients can be more easily identiﬁed [89]. Lastly, it
is important to be aware in a few speciﬁc situations the FSG can be normal in a ZES patient. This can
occurs after tumor resection, which is not curative, after antitumour treatments such as chemo-
therapy, or in MEN1/ZES patients after a successful parathyroidectomy for hyperparathyroidism
(usually 3.5-4-gland removal) [58,84,92,93].
Because of the high frequency of MEN1 in patients with ZES (20–25%) it is essential that this
diagnosis be explored for in all patients with ZES [46,51,58]. Besides a careful personal and family
history for endocrinopathies and peptic/GERD disease it is usually excluded by determining a plasma
ionized calcium, parathormone level (intact, IRMA assay) and assessment of plasma prolactin.
Although MEN1/ZES patients can present with ZES (up to 30%) [51,83], they almost invariably have
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the appropriate calcium determination or parathormone determination is not performed [51,83]. The
recognition of MEN1 is essential because these patients need to be followed carefully for other
endocrinopathies, family investigation would be indicated and the response to different treatment
differs from sporadic cases [46,51,58,82].
ZES: medical-treatment
Medical treatment of ZES involves treatment of the gastric acid hypersectrory state (acute,
chronic),treatment of endocrinopathies that develop in MEN1/ZES patients, treatment of effects of
long-term hypergastrinemia (gastric carcinoids in MEN1/ZES patients); treatment of other hormonal
syndromes that may develop and antitumour treatment of advanced metastatic disease [4,81,82,94].
The later is covered in separate chapters in this volume and will not be dealt with further here. The
drugs of choice to control the gastric acid hypersecretion both acutely and long-term are the PPIs
(omeprazole, lansoprazole, rabeprazole, esomeprazole, pantoprazole), because of their potency and
long durations of action that allow once or twice a day dosing in almost every patient [4,81,82,94].
Histamine H2 receptor antagonists (cimetidine, ranitidine, nizatidine, famotidine)(H2-R blockers) are
also effective, however high, frequent (every 4–6 h) dosing is usually required [81,82,94]. Patients
have been treated for longer than 20 years with PPIs and >10 years with H2R blockers and these
drugs have continued to remain effective. On the average 1 dose change per year is need with H2R-
blockers, whereas the dosing with PPIs generally remains stable or in some cases can even be
decreased with time [81,94,95]. Patients with complicated ZES (moderate-severe GERD,MEN1/ZES or
post Billroth 2 resections) characteristically require both higher doses of PPIs and more frequent
dosing(usually BID, occasional TID) [81,94,95]. Long-term treatment with PPIs has proved safe with
the only side effects due to PPI-induced achlorhydria, which can result in vitamin B12 deﬁciency
[94,96,97]. Although recent studies report in populations taking chronically taking PPIs an increased
incidence of bone fractures, at present there are no such reports in ZES patients [97]. One potential
side-effects is that, similar to seen in animal studies, chronic PPI treatment might increase the
possibility of developing gastric carcinoids, which ZES patients are already predisposed to, because
most have life-long hypergastrinemia, became surgical cure is only possible in <50% of patients with
sporadic ZES and almost no patients with MEN1/ZES [4,81,82,94,98]. Although studies show chronic
hypergastrinemia induces gastric ECL cell hyperplasia in almost all patients with ZES, that it is more
severe in patients with MEN1/ZES than sporadic ZES, that gastric carcinoids develop in 20–30% of
MEN1/ZES patients and <1% of sporadic ZES, there is no evidence that suggests the use of PPIs ac-
celerates their development [94,99,100]. Some patients in their disease course are unable to take oral
gastric antisecretory agents after surgery, chemotherapy, other antitumour treatments and paren-
teral administration is required. Both intravenous PPIs such as with pantoprazole [101] or with H2-
blockers such as ranitidine or cimetidine [94] have been shown to be effective for prolonged periods
of time [94]. The intravenous administration of PPIs is the preferred treatment because it can be
administered every 8–12 hours intermittently and relatively low doses are effective, whereas with
H2-blockers such as ranitidine or cimetidine a continuous infusion of relatively high doses is required
[94,101].
Patients with MEN1/ZES almost invariably develop other functional endocrinopathies with hy-
perparathyroidism being the most common, occurring in almost every patient [46,51]. The hyper-
parathyroidism is due to parathyroid hyperplasia and requires a 3.5 gland or 4-gland resection with an
implant and even then is frequently recurrent [46,51,84]. Most patients receive repeat para-
thyroidectomies, although now medical treatment has become a possibility with the availability of
cincalcet, a calcium sensing receptor allosteric modulator, which has successfully controlled the hy-
perparathyroidism in a small number of MEN1 patients [94,102]. Also patients with both sporadic ZES
and MEN1/ZES can develop other functional pNET/endocrine syndromes including Cushing’s syn-
drome (usually due to ectopic ACTH secretion by the pNET in sporadic and to a pituitary adenoma in
MEN/ZES) [94,103],as well as other functional pNET syndromes, especially those patients with MEN1/
ZES (insulinoma, occasional glucagonoma, carcinoid syndrome) [46,51,94]. Cushings disease in MEN1/
ZES patients is usually treated with pituitary surgery, whereas the ACTHoma in sporadic cases is
treated medically initially and then frequently with adrenalectomy, as covered in the later section on
T. Ito et al. / Best Practice & Research Clinical Gastroenterology 26 (2012) 737–753 747treatment of ACTHomas [46,51,94]. Other functional pNETs are treated surgically if possible,but if
advanced metastatic disease is present they are treated with long acting somatostatin analogues
(octreotide-LAR, lanreotide-autogel) to control the hormonal symptoms and antitumour agents to
control the tumor growth [3,94].
VIPoma
VIPoma: clinical-presentation
VIPomas characteristically present with large volume, watery diarrhoea that leads to the devel-
opment of dehydration and hypokalemia [2,69,104]. The excess VIP secretion also can result in hy-
perglycemia (20–50%),hypercalcaemia (25–50%), hypochlorhydria (20–50%) and ﬂushing (15–30%)
[2,69,104].
VIPoma: diagnosis/differential-diagnosis
The diagnosis is established by documenting the presence of large volume diarrhoea (usually >3 L
per day,and a VIPoma is generally excluded if the stool volume is <700 ml/day) that is secretory in
nature (no osmolar gap in the stool ﬂuid) and is accompanied by an increase plasma VIP level (usually
>500 pg/mL) (nl usually<190 pg/ml [2,69,104]. Other diseases that can give large volume diarrhoea
and can mimic VIPomas, but are not associated with an increased plasma VIP level, include Zollinger-
Ellison syndrome, chronic laxative abuse, sprue,AIDS,and rarely secretory diarrhoea of unknown origin
[2,34,69]. Most patients with VIPomas present with advanced disease with liver metastases that is
evident on somatostatin receptor scintigraphy (SRS) (Octreoscan), which should suggest the diagnosis.
In children the VIPoma syndrome can be due to a ganglioneuroma, rather that a pancreatic pNET [2,69].
VIPoma: medical-treatment
It is essential to control the high volume diarrhoea of VIPomas because it can lead to dehydration,
severe electrolyte abnormalities, renal failure and death. In addition to ﬂuid and electrolyte
replacement, long-acting somatostatin analogues (octreotide-LAR, lanreotide-autogel) are now the
drugs of choice and will control the diarrhoea in>90% of patients [2,69]. Other drugs that can be
effective in some patients and that were used prior to the availability of long acting somatostatin
analogues include glucocorticoids, clonidine, metoclopramide, loperamide, and lidamidine [69]. In
some patients surgical debulking of the tumor has been claimed to facilitate medical treatments and
be beneﬁcial, as well as other antitumour treatments, which are considered in other chapters in this
volume.
Glucagonoma
Glucagonoma: clinical-presentation
Glucagonomas characteristically present with a speciﬁc dermatitis(necrolytic migratory erythema
(NME))(55–90%), weight loss (60–90%),diabetes mellitus or glucose intolerance(30–90%),mucosal ab-
normalities (glossitis, cheilitis, stomatitis) (30–40%),diarrhoea (10–15%) and on laboratory studies,
anaemia is frequent(30–80%) as well as hypoaminoacidemia (30–100%) [69,105,106]. At presentation
glucagonomas are characterically large tumors (>5 cm) and in 50–80% of patients have advanced
disease with metastic liver lesions [69,105,106].
Glucagonoma: diagnosis/differential-diagnosis
In many cases a dermatologist, because of the characteristic skin lesion, NME, ﬁrst suspects the
diagnosis. NME, although suggestive of glucagonoma is not speciﬁc for this diagnosis as it also occurs
with liver diseases (cirrhosis, hepatitis, liver tumors),pancreatitis, celiac disease and lung cancer [69].
The diagnosis is established by documenting the presence of hyperglucagonemiawith diagnostic levels
generally >500 pg/ml (nl < 120). It is important to remember that other diseases can also cause
hyperglucagonemia including cirrhosis, pancreatitis, diabetes mellitus, prolonged fasting, sepsis,
burns, renal failure, acromegaly and familial hyperglucagonemia [69]. In the majority of cases com-
bined with the hyperglucagonemia and clinical symptoms/signs is the presence of metastatic disease
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ceptor-scintigraphy.
Glucagonoma: medical-treatment
The symptoms of gluconoma are now primarily treated with the use of somatostatin analogues
(octreotide-LAR, lanreotide-autogel) [2,69]. Using these analogues the rash, NME, is controlled in 50–
90%, and weight loss, abdominal pain and diarrhoea are usually improved, however, the diabetes
mellitus generally does not improve [2,69]. Because of the cachexia, hypoaminoacidemia, and weight
loss, parenteral nutrition is frequently used and is reported to havemarkedly improve the NME in some
patients [2,69]. Similar to patients with VIPomas, these patients characteristically have advanced
metastatic disease at presentation, and therefore in most patients anti-tumour therapies need to be
started and even consideration to cytoreductive surgery, which is reported to be helpful in these pa-
tients [69]. Each of these issues is considered in separate chapters in this volume.
Somatostatinomas (SSomas)
SSomas: clinical-presentation
The deﬁnition of what constitutes an SSoma is not generally agreed on in the literature [2,69]. Most
cases of SSomas in the literature do not have the clinical SSoma syndrome, characterized by diabetes
mellitus, gallbladder disease, diarrhoea, weight loss, and steatorrhea [2,69,107], but are cases of GI-
NETs with no speciﬁc symptoms or found by chance that demonstrate immunohistochemical stain-
ing for somatostatin-like-immunoreactivity (SLI). Therefore, it has been proposed the term SSoma
syndrome be used for an SSoma with the presence of the clinical syndrome and SSoma for the others
[2,69]. Characteristically pancreatic SSomas are associated with the SSoma syndrome, whereas small
intestinal SSomas are not [2,69,107].
SSomas: diagnosis/differential-diagnosis
In most cases SSomas are not diagnosed prior to surgery/biopsy. Most duodenal SSomas (98%) do
not produce the SSoma syndrome and present with abdominal pain, weight loss, jaundice and diar-
rhoea, which are not speciﬁc for SSoma, or suggest the diagnosis [2,69,107]. To diagnose the SSoma
syndrome plasma SLI levels need to be assessed. It is important to remember that a number of other
conditions are also associatedwith elevated plasma SLI levels including;medullary thyroid cancer, lung
cancers, pheochromocytomas and paragangliomas [2,69]. A peri-ampullary or duodenal SSoma should
raise the possibility of von Recklinghausen’s disease as discussed earlier (Table 3).
SSomas: medical-treatment
Patients with SSoma syndrome frequently require nutrition support or hyperalimentation. Treat-
ment with the long-acting somatostatin analogues (octreotide-LAR, lanreotide-autogel) has been
successful in a few cases in the literature [2,69].
GRFomas
GRFoma: clinical-presentation
GRFomas characteristically present with acromegaly which clinically resembles that seen with
pituitary adenomas, although some patients present with symptoms due to the primary tumor or with
advanced disease [2,69,108].
GRFoma: diagnosis/differential-diagnosis
GRFomas in most series are most frequently reported in the lung (50%), pancreas (30%) or small
intestine (8–10%) [2,69], however in a recent French National series (21 cases) the most frequent
location was the pancreas (57%) [108]. GRFomas make up <1% of all causes of acromegaly so a high
degree of suspicion is needed to diagnose them, especially since their clinical features of acromegaly
are not distinctive [108]. GRFomas should be suspected in patients with acromegaly without a pituitary
adenoma, with a paradoxical growth hormone response toTSH or glucose-load or if an abdominalmass
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demonstrating and elevated plasma GH-releasing factor level (GH-RF) [2,69,108].
GRFoma: medical-treatment
To control the hormone-excess state, long-acting somatostatin analogues (octreotide-LAR,
lanreotide-autogel) are the drugs of choice. Surgical resection of the primary pNET should be done
whenever possible but unfortunately metastases are already present at diagnosis in 30–50%, so anti-
tumour treatments may be needed, as outline in separate chapters in this volume [2,69,108].
Nonfunctional pNETs (NF-pNETs)
NF-pNET: clinical-presentation
NF-PETs are not associatedwith any functional syndrome, therefore their symptoms at presentation
are due to the tumor per se and characteristically include: abdominal pain (35–55%), jaundice (25–
40%),weight loss (30–45%) and/or an abdominal mass (10–40%) [2,11,69].Because the symptoms are
nonspeciﬁc, NF-PETs are usually diagnosed late in their disease course with large primaries (mean-4–
6 cm), with most have metastatic disease in the liver (40–90%) [2,11,69]. The term NF-PET is actual
a misnomer, even though widely used, because even though these tumors produce no functional pNET
syndrome, they are not non-functional in that they secrete may peptides that do not cause clinical
syndromes including pancreatic polypeptide (25–70%)(hence the alternative name, PPomas),
chromogranin-A (60–100%), neuron-speciﬁc enolase (31%),ghrelin, neurotensin, and subunits of
human chorionic-gonadotrophin (20%)(a/b-subunits) [2,11,69].
NF-pNET: diagnosis/differential-diagnosis
Because NF-PETs produce no speciﬁc functional syndrome, they can only be diagnosed preopera-
tivelywith a high degree of suspicion. A patient with extensivemetastases in the liver with a pancreatic
mass and relatively few symptoms, with minimal signs of advanced metastatic disease, with a positive
somatostatin receptor scintigraphy or with a plasma elevation of one of the nonspeciﬁc NET tumor
markers (pancreatic polypeptide, chromogranin-A, neuron-speciﬁc enolase) should be suspected of
having an NF-pNET. In 15–35% of patients the NF-pNET is found incidentally at surgery and in >50% of
the cases the diagnosis is only suspected after a biopsy is performed.
NF-pNET: medical-treatment
NF-pNETs because they have no functional syndrome are treated medically only for an anti-tumour
effect which is covered by other chapters in this volume.Practice points
 pNETs should be considered separately from GI carcinoid tumors
 pNETs can be either functional (F-pNET) or nonfunctional (NF-pNET)
 F-pNETs are divided into 9 established subtypes depending on the clinical hormonal syn-
drome manifested
 Other rarer subtypes of F-pNETs are reported in small numbers of cases (1-5 patients)
 F-pNETs are diagnosed by the presence of clinical evidence of hormone oversecretion and
elevated levels of the hormones in plasma
 F-pNETs are often misdiagnosed because their presentation may mimic other more common
diseases resulting in delays in diagnosis
 With F-pNETs the hormone-excess state must be controlled because if not, it can lead to
severe morbidity as well as death. This has been greatly facilitated by a number of new drugs
over that last 20 years.
 pNETs except insulinomas are malignant in >50% of cases so treatment must be directed
against the tumor itself in addition to the hormone-excess state if present
Research points
 The pathogenesis of pNETs needs to be better deﬁned so new forms of treatment can be
developed
 Plasma hormonal assays, which are widely used to diagnose F-pNETs, need to be much better
characterized and standardized in different laboratories offering this service.
 pNETs because they are uncommon, are best-treated and followed in specialty centers where
systematic assessments of new therapies can be carried out.
 New treatments should be systematically compared to assess which of the large number of
new therapies is the most effective
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